I would have thought there would be more volume and interest than there has been of late. It's been on a nice run since mid December 2016 after a shareholder conference call. Since December, we've seen a lot of good news and the stock price has started to reflect it. I think the next big price mover of the stock is when they release a statement or update when their Phase 3 trial has begun. Until the completion of Phase 3, trial results, and FDA status, I think it'll trade around these $3.90 - 4.20. Might be a good time to buy on a small dip. There's been a lot of good PR's this year and two stick out;
1. 2/21 PR - BCLI is seeking approval to distribute in Canada. This is good news because if approved, they could be treating patients in Canada and generating revenue. keep in mind the company is debt free and has done a great job limiting dilutive shares to raise capital.
2. 3/6 - Ralph Kern joins BCLI management team. I think this PR was overlooked because Kern came from large pharmaceutical companies (Biogen and Novartis) to work for BCLI. he has extensive knowledge of worldwide distribution and the fact that he left Biogen to join a company with approximately 15 employees speaks volumes.
News 
Market Data 
Discover 
